Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarkers of response to PD-1 pathway blockade
Hanxiao Li, P. Anton van der Merwe, Shivan Sivakumar
British Journal of Cancer (2022) Vol. 126, Iss. 12, pp. 1663-1675
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Applications of single-cell RNA sequencing in drug discovery and development
Bram Van de Sande, Joon Sang Lee, Euphemia Mutasa-Gottgens, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 496-520
Open Access | Times Cited: 199
Thermal immuno-nanomedicine in cancer
Zhe Yang, Di Gao, Jing Zhao, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 116-134
Closed Access | Times Cited: 143
Regulatory cells and the effect of cancer immunotherapy
María Iglesias-Escudero, Noelia Arias-González, Eva Martínez‐Cáceres
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 498-512
Closed Access | Times Cited: 60
The artificial intelligence and machine learning in lung cancer immunotherapy
Qing Gao, Luyu Yang, Mingjun Lu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 52
Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Magdalena Matusiak, John W. Hickey, David G.P. van IJzendoorn, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1418-1439
Open Access | Times Cited: 30
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer
Jie Mei, Yun Cai, Hongjun Zhu, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 16
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
Eftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
EBioMedicine (2023) Vol. 93, pp. 104644-104644
Open Access | Times Cited: 24
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, et al.
Biomolecules (2023) Vol. 13, Iss. 12, pp. 1803-1803
Open Access | Times Cited: 24
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 13
Ionizable Lipid Nanoparticle-Mediated TRAIL mRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression
Walison da Silva, Pedro Augusto Carvalho Costa, Sérgio Ricardo Scalzo Júnior, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 2655-2673
Open Access | Times Cited: 12
Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy
Fusheng Si, Xia Liu, Yan Tao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008219-e008219
Open Access | Times Cited: 11
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 11
An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome
Shuaiming Jiang, Wenyao Ma, Chenchen Ma, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers
Rumiana Tenchov, Aparna K. Sapra, Janet M. Sasso, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 586-613
Open Access | Times Cited: 9
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 29-38
Closed Access | Times Cited: 9
Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage
Naoe Taira Nihira, Wenwen Wu, M Hosoi, et al.
EMBO Reports (2025)
Open Access | Times Cited: 1
Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1
Fabian Krutzek, Cornelius K. Donat, Martin Ullrich, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2638-2638
Open Access | Times Cited: 20
Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis
Zhi Xiong Chong, Chean Yeah Yong, Han Kiat Ong, et al.
Toxicology (2023) Vol. 495, pp. 153596-153596
Open Access | Times Cited: 17
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Chowdhury Arif Jahangir, David B. Page, Glenn Broeckx, et al.
The Journal of Pathology (2024) Vol. 262, Iss. 3, pp. 271-288
Open Access | Times Cited: 6
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Eva Ellebæk, Shawez Khan, Lars Bastholt, et al.
European Journal of Cancer (2023) Vol. 198, pp. 113476-113476
Open Access | Times Cited: 16
A spatial map of human macrophage niches reveals context-dependent macrophage functions in colon and breast cancer.
Magdalena Matusiak, John W. Hickey, Bogdan Luca, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 14
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors
Olga Blomberg, Kevin Kos, Lorenzo Spagnuolo, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
The Role of Regulatory T Cells in Cancer Treatment Resistance
Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14114-14114
Open Access | Times Cited: 11
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders
Brandon M. Huffman, Harshabad Singh, Lestat R. Ali, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008436-e008436
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top